Log In
Print
BCIQ
Print
Print this Print this
 

Ozanezumab (1223249)

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionHumanized mAb against reticulon 4 NOGO
Molecular Target Reticulon 4 (RTN4) (NOGO-A) (NOGO) (NOGO-B)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAmyotrophic lateral sclerosis (ALS)
Indication DetailsTreat amyotrophic lateral sclerosis (ALS)
Regulatory Designation

Japan - Orphan Drug (Treat amyotrophic lateral sclerosis (ALS))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today